[Frontiers in Bioscience, Landmark, 25, 242-269, Jan 1, 2020]

Anti-inflammatory therapy in atherosclerosis

Duygu Kocyigit1, Kadri M Gurses2, Lale Tokgozoglu3

1Cardiology Clinics, Afyonkarahisar Dinar State Hospital, 03400, Afyonkarahisar, Turkey, 2Department of Basic Medical Sciences, Adnan Menderes University Faculty of Medicine, 09010, Aydin, Turkey, 3Department of Cardiology, Hacettepe University Faculty of Medicine, 06100, Ankara, Turkey


1. Abstract
2. Introduction
3. Anti-inflammatory drugs
    3.1. Anti-inflammatory drugs with low probability to improve cardiovascular outcomes
      3.1.1. Corticosteroids
      3.1.2. Pexelizumab
      3.1.3. Tranilast
      3.1.4. Anti-tumor necrosis factor (anti-TNF) therapy
      3.1.5. Phospholipase A2 (PLA2) inhibitors
      3.1.6. Losmapimod
      3.1.7. Salsalate
      3.1.8. Interleukin-1 receptor antagonists (IL-1Ra)
      3.1.9. Methotrexate
    3.2. Anti-inflammatory drugs with probability to improve cardiovascular outcomes
      3.2.1. Colchicine
      3.2.2. Tocilizumab
    3.3. Anti-inflammatory drugs currently being tested in cardiovascular outcome studies
      3.3.1. Canakinumab
      3.3.2. Rituximab
    3.4. Possible future anti-inflammatory drug targets for treatment of atheroclerosis
4. References


Cardiovascular disease (CVD) is the leading cause of death. Although once considered merely as a lipid storage disease, studies indicate the role of inflammation in initiation and progression of atherosclerotic CVD, as well as the development of thrombotic complications. Despite significant advances in treatment of atherosclerosis, there still exists a residual risk for CVD-related morbidity and mortality. Even with optimal treatment, the rate of a new event after an index acute coronary syndrome event, such as myocardial ischemia or infarction, in the first three years has been reported to be as high as 20%. In the last decades, inflammation due to apoB-lipoproteins and other traditional risk factors, such as hypertension, diabetes and smoking, is accepted as a new target for CVD prevention. Up to now, several anti-inflammatory drugs have been tested for use in atherosclerosis. This review focuses on the current status of anti-inflammatory drug therapy for atherosclerotic CVD in humans.


1. http://www.who.int/mediacentre/factshe-ets/fs317/en/

2. J. F. Bentzon: Targeting Inflammation in Atherosclerosis. J Am Coll Cardiol, 68 (25), 2794-2796 (2016)
DOI: 10.1016/j.jacc.2016.11.005

3. G. W. Stone, A. Maehara, A. J. Lansky, B. de Bruyne, E. Cristea, G. S. Mintz, R. Mehran, J. McPherson, N. Farhat, S. P. Marso, H. Parise, B. Templin, R. White, Z. Zhang, P. W. Serruys and P. Investigators: A prospective natural-history study of coronary atherosclerosis. N Engl J Med, 364 (3), 226-35 (2011)
DOI: 10.1056/NEJMoa1002358

4. J. R. Downs, M. Clearfield, S. Weis, E. Whitney, D. R. Shapiro, P. A. Beere, A. Langendorfer, E. A. Stein, W. Kruyer and A. M. Gotto, Jr.: Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels: results of AFCAPS/TexCAPS. Air Force/Texas Coronary Atherosclerosis Prevention Study. JAMA, 279 (20), 1615-22 (1998)
DOI: 10.1001/jama.279.20.1615

5. G. Long-Term Intervention with Pravastatin in Ischaemic Disease Study: Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med, 339 (19), 1349-57 (1998)
DOI: 10.1056/NEJM199811053391902

6. P. M. Ridker, E. Danielson, F. A. Fonseca, J. Genest, A. M. Gotto, Jr., J. J. Kastelein, W. Koenig, P. Libby, A. J. Lorenzatti, J. G. MacFadyen, B. G. Nordestgaard, J. Shepherd, J. T. Willerson, R. J. Glynn and J. S. Group: Rosuvastatin to prevent vascular events in men and women with elevated C-reactive protein. N Engl J Med, 359 (21), 2195-207 (2008)
DOI: 10.1056/NEJMoa0807646

7. O. Kwon, S. J. Kang, S. H. Kang, P. H. Lee, S. C. Yun, J. M. Ahn, D. W. Park, S. W. Lee, Y. H. Kim, C. W. Lee, K. H. Han, S. W. Park and S. J. Park: Relationship Between Serum Inflammatory Marker Levels and the Dynamic Changes in Coronary Plaque Characteristics After Statin Therapy. Circ Cardiovasc Imaging, 10 (7) (2017)
DOI: 10.1161/CIRCIMAGING.116.005934

8. P. J. Barnes: Anti-inflammatory actions of glucocorticoids: molecular mechanisms. Clin Sci (Lond), 94 (6), 557-72 (1998)
DOI: 10.1042/cs0940557

9. A. Colao, R. Pivonello, S. Spiezia, A. Faggiano, D. Ferone, M. Filippella, P. Marzullo, G. Cerbone, M. Siciliani and G. Lombardi: Persistence of increased cardiovascular risk in patients with Cushing's disease after five years of successful cure. J Clin Endocrinol Metab, 84 (8), 2664-72 (1999)
DOI: 10.1210/jcem.

10. P. G. Vlachoyiannopoulos, P. G. Kanellopoulos, J. P. Ioannidis, M. G. Tektonidou, I. Mastorakou and H. M. Moutsopoulos: Atherosclerosis in premenopausal women with antiphospholipid syndrome and systemic lupus erythematosus: a controlled study. Rheumatology (Oxford), 42 (5), 645-51 (2003)
DOI: 10.1093/rheumatology/keg182

11. K. Manger, M. Kusus, C. Forster, D. Ropers, W. G. Daniel, J. R. Kalden, S. Achenbach and B. Manger: Factors associated with coronary artery calcification in young female patients with SLE. Ann Rheum Dis, 62 (9), 846-50 (2003)
DOI: 10.1136/ard.62.9.846

12. I. del Rincon, D. H. O'Leary, R. W. Haas and A. Escalante: Effect of glucocorticoids on the arteries in rheumatoid arthritis. Arthritis Rheum, 50 (12), 3813-22 (2004)
DOI: 10.1002/art.20661

13. P. C. Souverein, A. Berard, T. P. Van Staa, C. Cooper, A. C. Egberts, H. G. Leufkens and B. R. Walker: Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study. Heart, 90 (8), 859-65 (2004)
DOI: 10.1136/hrt.2003.020180

14. L. Wei, T. M. MacDonald and B. R. Walker: Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease. Ann Intern Med, 141 (10), 764-70 (2004)
DOI: 10.7326/0003-4819-141-10-200411160-00007

15. J. M. Davis, 3rd, H. Maradit Kremers, C. S. Crowson, P. J. Nicola, K. V. Ballman, T. M. Therneau, V. L. Roger and S. E. Gabriel: Glucocorticoids and cardiovascular events in rheumatoid arthritis: a population-based cohort study. Arthritis Rheum, 56 (3), 820-30 (2007)
DOI: 10.1002/art.22418

16. A. Uddhammar, A. L. Eriksson, L. Nystrom, R. Stenling and S. Rantapaa-Dahlqvist: Increased mortality due to cardiovascular disease in patients with giant cell arteritis in northern Sweden. J Rheumatol, 29 (4), 737-42 (2002)

17. H. Maradit Kremers, M. S. Reinalda, C. S. Crowson, J. M. Davis, 3rd, G. G. Hunder and S. E. Gabriel: Glucocorticoids and cardiovascular and cerebrovascular events in polymyalgia rheumatica. Arthritis Rheum, 57 (2), 279-86 (2007)
DOI: 10.1002/art.22548

18. G. R. Giugliano, R. P. Giugliano, C. M. Gibson and R. E. Kuntz: Meta-analysis of corticosteroid treatment in acute myocardial infarction. Am J Cardiol, 91 (9), 1055-9 (2003)
DOI: 10.1016/S0002-9149(03)00148-6

19. F. Versaci, A. Gaspardone, F. Tomai, F. Ribichini, P. Russo, I. Proietti, A. S. Ghini, V. Ferrero, L. Chiariello, P. A. Gioffre, F. Romeo, F. Crea and S. Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation: Immunosuppressive Therapy for the Prevention of Restenosis after Coronary Artery Stent Implantation (IMPRESS Study). J Am Coll Cardiol, 40 (11), 1935-42 (2002)
DOI: 10.1016/S0735-1097(02)02562-7

20. T. Kakio, A. Matsumori, N. Ohashi, T. Yamada, T. Saito, A. Kawamoto, A. Taguchi, Y. Morita, M. Takahashi and S. Sasayama: Hydrocortisone reduces restenosis after stenting of small coronary arteries. J Interv Cardiol, 17 (5), 295-300 (2004)
DOI: 10.1111/j.1540-8183.2004.02999.x

21. T. Kakio, A. Matsumori, N. Ohashi, T. Yamada, M. Nobuhara, T. Saito, A. Kawamoto, A. Taguchi, Y. Morita, M. Takahashi and S. Sasayama: The effect of hydrocortisone on reducing rates of restenosis and target lesion revascularization after coronary stenting less than 3 mm in stent diameter. Intern Med, 42 (11), 1084-9 (2003)

22. V. Ferrero, F. Ribichini, A. Rognoni, P. Marino, S. Brunelleschi and C. Vassanelli: Comparison of efficacy and safety of lower-dose to higher-dose oral prednisone after percutaneous coronary interventions (the IMPRESS-LD study). Am J Cardiol, 99 (8), 1082-6 (2007)
DOI: 10.1016/j.amjcard.2006.11.064

23. C. J. Pepine, J. W. Hirshfeld, R. G. Macdonald, M. A. Henderson, T. A. Bass, S. Goldberg, M. P. Savage, G. Vetrovec, M. Cowley, A. S. Taussig and et al.: A controlled trial of corticosteroids to prevent restenosis after coronary angioplasty. M-HEART Group. Circulation, 81 (6), 1753-61 (1990)

24. C. W. Lee, J. K. Chae, H. Y. Lim, M. K. Hong, J. J. Kim, S. W. Park and S. J. Park: Prospective randomized trial of corticosteroids for the prevention of restenosis after intracoronary stent implantation. Am Heart J, 138 (1 Pt 1), 60-3 (1999)
DOI: 10.1016/S0002-8703(99)70247-4

25. G. W. Stone, B. D. Rutherford, D. R. McConahay, W. L. Johnson, L. V. Giorgi, R. W. Ligon and G. O. Hartzler: A randomized trial of corticosteroids for the prevention of restenosis in 102 patients undergoing repeat coronary angioplasty. Cathet Cardiovasc Diagn, 18 (4), 227-31 (1989)
DOI: 10.1002/ccd.1810180407

26. B. Reimers, I. I. Moussa, T. Akiyama, Y. Kobayashi, R. Albiero, L. Di Francesco, C. Di Mario and A. Colombo: Persistent High Restenosis After Local Intrawall Delivery of Long-Acting Steroids Before Coronary Stent Implantation. J Invasive Cardiol, 10 (6), 323-331 (1998)

27. S. T. Rab, S. B. King, 3rd, G. S. Roubin, S. Carlin, J. A. Hearn and J. S. Douglas, Jr.: Coronary aneurysms after stent placement: a suggestion of altered vessel wall healing in the presence of anti-inflammatory agents. J Am Coll Cardiol, 18 (6), 1524-8 (1991)
DOI: 10.1016/j.jcin.2007.10.004

28. M. R. Ward, P. Kanellakis, D. Ramsey, J. Funder and A. Bobik: Eplerenone suppresses constrictive remodeling and collagen accumulation after angioplasty in porcine coronary arteries. Circulation, 104 (4), 467-72 (2001)
DOI: 10.1161/hc3001.091458

29. G. Patti, M. Chello, V. Pasceri, D. Colonna, P. Carminati, E. Covino and S. Di Germano: Dexamethasone-eluting stents and plasma concentrations of adhesion molecules in patients with unstable coronary syndromes: results of the historically controlled SESAME study. Clin Ther, 27 (9), 1411-9 (2005)
DOI: 10.1016/j.clinthera.2005.09.009

30. G. Patti, V. Pasceri, P. Carminati, A. D'Ambrosio, A. Carcagni and G. Di Sciascio: Effect of dexamethasone-eluting stents on systemic inflammatory response in patients with unstable angina pectoris or recent myocardial infarction undergoing percutaneous coronary intervention. Am J Cardiol, 95 (4), 502-5 (2005)
DOI: 10.1016/j.amjcard.2004.10.021

31. X. Liu, Y. Huang, C. Hanet, M. Vandormael, V. Legrand, J. Dens, J. L. Vandenbossche, L. Missault, C. Vrints and I. De Scheerder: Study of antirestenosis with the BiodivYsio dexamethasone-eluting stent (STRIDE): a first-in-human multicenter pilot trial. Catheter Cardiovasc Interv, 60 (2), 172-8; discussion 179 (2003)
DOI: 10.1002/ccd.10636

32. R. S. Fishel, S. Eisenberg, S. Y. Shai, R. A. Redden, K. E. Bernstein and B. C. Berk: Glucocorticoids induce angiotensin-converting enzyme expression in vascular smooth muscle. Hypertension, 25 (3), 343-9 (1995)
DOI: 10.1161/01.HYP.25.3.343

33. F. A. Mendelsohn, C. J. Lloyd, C. Kachel and J. W. Funder: Induction by glucocorticoids of angiotensin converting enzyme production from bovine endothelial cells in culture and rat lung in vivo. J Clin Invest, 70 (3), 684-92 (1982)
DOI: 10.1172/JCI110663

34. C. Morin, C. Asselin, F. Boudreau and P. H. Provencher: Transcriptional regulation of pre-pro-endothelin-1 gene by glucocorticoids in vascular smooth muscle cells. Biochem Biophys Res Commun, 244 (2), 583-7 (1998)
DOI: 10.1006/bbrc.1998.8300

35. G. J. Mangos, B. R. Walker, J. J. Kelly, J. A. Lawson, D. J. Webb and J. A. Whitworth: Cortisol inhibits cholinergic vasodilation in the human forearm. Am J Hypertens, 13 (11), 1155-60 (2000)
DOI: 10.1016/S0895-7061(00)01201-2

36. K. Yasojima, C. Schwab, E. G. McGeer and P. L. McGeer: Human heart generates complement proteins that are upregulated and activated after myocardial infarction. Circ Res, 83 (8), 860-9 (1998)
DOI: 10.1161/01.RES.83.8.860

37. M. M. Markiewski, B. Nilsson, K. N. Ekdahl, T. E. Mollnes and J. D. Lambris: Complement and coagulation: strangers or partners in crime? Trends Immunol, 28 (4), 184-92 (2007)
DOI: 10.1016/j.it.2007.02.006

38. L. Testa, W. J. Van Gaal, R. Bhindi, G. G. Biondi-Zoccai, A. Abbate, P. Agostoni, I. Porto, F. Andreotti, F. Crea and A. P. Banning: Pexelizumab in ischemic heart disease: a systematic review and meta-analysis on 15,196 patients. J Thorac Cardiovasc Surg, 136 (4), 884-93 (2008)
DOI: 10.1016/j.jtcvs.2007.12.062

39. H. Suzawa, S. Kikuchi, N. Arai and A. Koda: The mechanism involved in the inhibitory action of tranilast on collagen biosynthesis of keloid fibroblasts. Jpn J Pharmacol, 60 (2), 91-6 (1992)
DOI: 10.1254/jjp.60.91

40. D. R. Holmes, Jr., M. Savage, J. M. LaBlanche, L. Grip, P. W. Serruys, P. Fitzgerald, D. Fischman, S. Goldberg, J. A. Brinker, A. M. Zeiher, L. M. Shapiro, J. Willerson, B. R. Davis, J. J. Ferguson, J. Popma, S. B. King, 3rd, A. M. Lincoff, J. E. Tcheng, R. Chan, J. R. Granett and M. Poland: Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial. Circulation, 106 (10), 1243-50 (2002)
DOI: 10.1161/01.CIR.0000028335.31300.DA

41. L. T. Jacobsson, C. Turesson, A. Gulfe, M. C. Kapetanovic, I. F. Petersson, T. Saxne and P. Geborek: Treatment with tumor necrosis factor blockers is associated with a lower incidence of first cardiovascular events in patients with rheumatoid arthritis. J Rheumatol, 32 (7), 1213-8 (2005)

42. W. G. Dixon, K. D. Watson, M. Lunt, K. L. Hyrich, C. British Society for Rheumatology Biologics Register Control Centre, A. J. Silman, D. P. Symmons and R. British Society for Rheumatology Biologics: Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register. Arthritis Rheum, 56 (9), 2905-12 (2007)
DOI: 10.1002/art.22809

43. J. D. Greenberg, J. M. Kremer, J. R. Curtis, M. C. Hochberg, G. Reed, P. Tsao, M. E. Farkouh, A. Nasir, S. Setoguchi, D. H. Solomon and C. Investigators: Tumour necrosis factor antagonist use and associated risk reduction of cardiovascular events among patients with rheumatoid arthritis. Ann Rheum Dis, 70 (4), 576-82 (2011)
DOI: 10.1136/ard.2010.129916

44. D. H. Solomon, J. R. Curtis, K. G. Saag, J. Lii, L. Chen, L. R. Harrold, L. J. Herrinton, D. J. Graham, M. K. Kowal, B. Kuriya, L. Liu, M. R. Griffin, J. D. Lewis and J. A. Rassen: Cardiovascular risk in rheumatoid arthritis: comparing TNF-alpha blockade with nonbiologic DMARDs. Am J Med, 126 (8), 730 e9-730 e17 (2013)
DOI: 10.1016/j.amjmed.2013.02.016

45. R. Bissonnette, J. C. Tardif, F. Harel, J. Pressacco, C. Bolduc and M. C. Guertin: Effects of the tumor necrosis factor-alpha antagonist adalimumab on arterial inflammation assessed by positron emission tomography in patients with psoriasis: results of a randomized controlled trial. Circ Cardiovasc Imaging, 6 (1), 83-90 (2013)
DOI: 10.1161/CIRCIMAGING.112.975730

46. M. A. Corson: Phospholipase A2 inhibitors in atherosclerosis: the race is on. Lancet, 373 (9664), 608-10 (2009)
DOI: 10.1016/S0140-6736(09)60378-0

47. P. L. A. S. C. Lp, A. Thompson, P. Gao, L. Orfei, S. Watson, E. Di Angelantonio, S. Kaptoge, C. Ballantyne, C. P. Cannon, M. Criqui, M. Cushman, A. Hofman, C. Packard, S. G. Thompson, R. Collins and J. Danesh: Lipoprotein-associated phospholipase A (2) and risk of coronary disease, stroke, and mortality: collaborative analysis of 32 prospective studies. Lancet, 375 (9725), 1536-44 (2010)
DOI: 10.1016/S0140-6736(10)60319-4

48. I. J. Hatoum, N. R. Cook, J. J. Nelson, K. M. Rexrode and E. B. Rimm: Lipoprotein-associated phospholipase A2 activity improves risk discrimination of incident coronary heart disease among women. Am Heart J, 161 (3), 516-22 (2011)
DOI: 10.1016/j.ahj.2010.11.007

49. S. J. Nicholls, J. J. Kastelein, G. G. Schwartz, D. Bash, R. S. Rosenson, M. A. Cavender, D. M. Brennan, W. Koenig, J. W. Jukema, V. Nambi, R. S. Wright, V. Menon, A. M. Lincoff, S. E. Nissen and V.-. Investigators: Varespladib and cardiovascular events in patients with an acute coronary syndrome: the VISTA-16 randomized clinical trial. JAMA, 311 (3), 252-62 (2014)
DOI: 10.1001/jama.2013.282836

50. M. S. Marber, B. Rose and Y. Wang: The p38 mitogen-activated protein kinase pathway--a potential target for intervention in infarction, hypertrophy, and heart failure. J Mol Cell Cardiol, 51 (4), 485-90 (2011)
DOI: 10.1016/j.yjmcc.2010.10.021

51. J. C. Lee, S. Kassis, S. Kumar, A. Badger and J. L. Adams: p38 mitogen-activated protein kinase inhibitors--mechanisms and therapeutic potentials. Pharmacol Ther, 82 (2-3), 389-97 (1999)
DOI: 10.1016/S0163-7258(99)00008-X

52. S. Kumar, J. Boehm and J. C. Lee: p38 MAP kinases: key signalling molecules as therapeutic targets for inflammatory diseases. Nat Rev Drug Discov, 2 (9), 717-26 (2003)
DOI: 10.1038/nrd1177

53. M. J. Yin, Y. Yamamoto and R. B. Gaynor: The anti-inflammatory agents aspirin and salicylate inhibit the activity of I (kappa)B kinase-beta. Nature, 396 (6706), 77-80 (1998)
DOI: 10.1038/23948

54. T. Chiba, Y. Kondo, S. Shinozaki, E. Kaneko, A. Ishigami, N. Maruyama, K. Umezawa and K. Shimokado: A selective NFkappaB inhibitor, DHMEQ, reduced atherosclerosis in ApoE-deficient mice. J Atheroscler Thromb, 13 (6), 308-13 (2006)
DOI: 10.5551/jat.13.308

55. R. Gareus, E. Kotsaki, S. Xanthoulea, I. van der Made, M. J. Gijbels, R. Kardakaris, A. Polykratis, G. Kollias, M. P. de Winther and M. Pasparakis: Endothelial cell-specific NF-kappaB inhibition protects mice from atherosclerosis. Cell Metab, 8 (5), 372-83 (2008)
DOI: 10.1016/j.cmet.2008.08.016

56. J. A. Mitchell, M. Saunders, P. J. Barnes, R. Newton and M. G. Belvisi: Sodium salicylate inhibits cyclo-oxygenase-2 activity independently of transcription factor (nuclear factor kappaB) activation: role of arachidonic acid. Mol Pharmacol, 51 (6), 907-12 (1997)
DOI: 10.1124/mol.51.6.907

57. P. Schwenger, D. Alpert, E. Y. Skolnik and J. Vilcek: Activation of p38 mitogen-activated protein kinase by sodium salicylate leads to inhibition of tumor necrosis factor-induced IkappaB alpha phosphorylation and degradation. Mol Cell Biol, 18 (1), 78-84 (1998)
DOI: 10.1128/MCB.18.1.78

58. B. N. Cronstein, M. C. Montesinos and G. Weissmann: Salicylates and sulfasalazine, but not glucocorticoids, inhibit leukocyte accumulation by an adenosine-dependent mechanism that is independent of inhibition of prostaglandin synthesis and p105 of NFkappaB. Proc Natl Acad Sci U S A, 96 (11), 6377-81 (1999)
DOI: 10.1073/pnas.96.11.6377

59. X. M. Xu, L. Sansores-Garcia, X. M. Chen, N. Matijevic-Aleksic, M. Du and K. K. Wu: Suppression of inducible cyclooxygenase 2 gene transcription by aspirin and sodium salicylate. Proc Natl Acad Sci U S A, 96 (9), 5292-7 (1999)
DOI: 10.1073/pnas.96.9.5292

60. T. H. Hauser, N. Salastekar, E. J. Schaefer, T. Desai, H. L. Goldfine, K. M. Fowler, G. M. Weber, F. Welty, M. Clouse, S. E. Shoelson, A. B. Goldfine and T. Targeting Inflammation Using Salsalate in Cardiovascular Disease Study: Effect of Targeting Inflammation With Salsalate: The TINSAL-CVD Randomized Clinical Trial on Progression of Coronary Plaque in Overweight and Obese Patients Using Statins. JAMA Cardiol, 1 (4), 413-23 (2016)
DOI: 10.1001/jamacardio.2016.0605

61. M. P. Bevilacqua, J. S. Pober, M. E. Wheeler, R. S. Cotran and M. A. Gimbrone, Jr.: Interleukin-1 activation of vascular endothelium. Effects on procoagulant activity and leukocyte adhesion. Am J Pathol, 121 (3), 394-403 (1985)

62. P. Libby, S. J. Warner and G. B. Friedman: Interleukin 1: a mitogen for human vascular smooth muscle cells that induces the release of growth-inhibitory prostanoids. J Clin Invest, 81 (2), 487-98 (1988)
DOI: 10.1172/JCI113346

63. H. Loppnow and P. Libby: Proliferating or interleukin 1-activated human vascular smooth muscle cells secrete copious interleukin 6. J Clin Invest, 85 (3), 731-8 (1990)
DOI: 10.1172/JCI114498

64. I. R. G. C. E. R. F. Collaboration, N. Sarwar, A. S. Butterworth, D. F. Freitag, J. Gregson, P. Willeit, D. N. Gorman, P. Gao, D. Saleheen, A. Rendon, C. P. Nelson, P. S. Braund, A. S. Hall, D. I. Chasman, A. Tybjaerg-Hansen, J. C. Chambers, E. J. Benjamin, P. W. Franks, R. Clarke, A. A. Wilde, M. D. Trip, M. Steri, J. C. Witteman, L. Qi, C. E. van der Schoot, U. de Faire, J. Erdmann, H. M. Stringham, W. Koenig, D. J. Rader, D. Melzer, D. Reich, B. M. Psaty, M. E. Kleber, D. B. Panagiotakos, J. Willeit, P. Wennberg, M. Woodward, S. Adamovic, E. B. Rimm, T. W. Meade, R. F. Gillum, J. A. Shaffer, A. Hofman, A. Onat, J. Sundstrom, S. Wassertheil-Smoller, D. Mellstrom, J. Gallacher, M. Cushman, R. P. Tracy, J. Kauhanen, M. Karlsson, J. T. Salonen, L. Wilhelmsen, P. Amouyel, B. Cantin, L. G. Best, Y. Ben-Shlomo, J. E. Manson, G. Davey-Smith, P. I. de Bakker, C. J. O'Donnell, J. F. Wilson, A. G. Wilson, T. L. Assimes, J. O. Jansson, C. Ohlsson, A. Tivesten, O. Ljunggren, M. P. Reilly, A. Hamsten, E. Ingelsson, F. Cambien, J. Hung, G. N. Thomas, M. Boehnke, H. Schunkert, F. W. Asselbergs, J. J. Kastelein, V. Gudnason, V. Salomaa, T. B. Harris, J. S. Kooner, K. H. Allin, B. G. Nordestgaard, J. C. Hopewell, A. H. Goodall, P. M. Ridker, H. Holm, H. Watkins, W. H. Ouwehand, N. J. Samani, S. Kaptoge, E. Di Angelantonio, O. Harari and J. Danesh: Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies. Lancet, 379 (9822), 1205-13 (2012)
DOI: 10.1016/S0140-6736(11)61931-4

65. C. Interleukin-6 Receptor Mendelian Randomisation Analysis, D. I. Swerdlow, M. V. Holmes, K. B. Kuchenbaecker, J. E. Engmann, T. Shah, R. Sofat, Y. Guo, C. Chung, A. Peasey, R. Pfister, S. P. Mooijaart, H. A. Ireland, M. Leusink, C. Langenberg, K. W. Li, J. Palmen, P. Howard, J. A. Cooper, F. Drenos, J. Hardy, M. A. Nalls, Y. R. Li, G. Lowe, M. Stewart, S. J. Bielinski, J. Peto, N. J. Timpson, J. Gallacher, M. Dunlop, R. Houlston, I. Tomlinson, I. Tzoulaki, J. Luan, J. M. Boer, N. G. Forouhi, N. C. Onland-Moret, Y. T. van der Schouw, R. B. Schnabel, J. A. Hubacek, R. Kubinova, M. Baceviciene, A. Tamosiunas, A. Pajak, R. Topor-Madry, S. Malyutina, D. Baldassarre, B. Sennblad, E. Tremoli, U. de Faire, L. Ferrucci, S. Bandenelli, T. Tanaka, J. F. Meschia, A. Singleton, G. Navis, I. Mateo Leach, S. J. Bakker, R. T. Gansevoort, I. Ford, S. E. Epstein, M. S. Burnett, J. M. Devaney, J. W. Jukema, R. G. Westendorp, G. Jan de Borst, Y. van der Graaf, P. A. de Jong, A. H. Mailand-van der Zee, O. H. Klungel, A. de Boer, P. A. Doevendans, J. W. Stephens, C. B. Eaton, J. G. Robinson, J. E. Manson, F. G. Fowkes, T. M. Frayling, J. F. Price, P. H. Whincup, R. W. Morris, D. A. Lawlor, G. D. Smith, Y. Ben-Shlomo, S. Redline, L. A. Lange, M. Kumari, N. J. Wareham, W. M. Verschuren, E. J. Benjamin, J. C. Whittaker, A. Hamsten, F. Dudbridge, J. A. Delaney, A. Wong, D. Kuh, R. Hardy, B. A. Castillo, J. J. Connolly, P. van der Harst, E. J. Brunner, M. G. Marmot, C. L. Wassel, S. E. Humphries, P. J. Talmud, M. Kivimaki, F. W. Asselbergs, M. Voevoda, M. Bobak, H. Pikhart, J. G. Wilson, H. Hakonarson, A. P. Reiner, B. J. Keating, N. Sattar, A. D. Hingorani and J. P. Casas: The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. Lancet, 379 (9822), 1214-24 (2012)
DOI: 10.1016/S0140-6736(12)60110-X

66. A. C. Morton, A. M. Rothman, J. P. Greenwood, J. Gunn, A. Chase, B. Clarke, A. S. Hall, K. Fox, C. Foley, W. Banya, D. Wang, M. D. Flather and D. C. Crossman: The effect of interleukin-1 receptor antagonist therapy on markers of inflammation in non-ST elevation acute coronary syndromes: the MRC-ILA Heart Study. Eur Heart J, 36 (6), 377-84 (2015)
DOI: 10.1093/eurheartj/ehu272

67. C. Interleukin 1 Genetics: Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelian randomisation analysis. Lancet Diabetes Endocrinol, 3 (4), 243-53 (2015)
DOI: 10.1016/S2213-8587(15)00034-0

68. A. Abbate, M. C. Kontos, J. D. Grizzard, G. G. Biondi-Zoccai, B. W. Van Tassell, R. Robati, L. M. Roach, R. A. Arena, C. S. Roberts, A. Varma, C. C. Gelwix, F. N. Salloum, A. Hastillo, C. A. Dinarello, G. W. Vetrovec and V.-A. Investigators: Interleukin-1 blockade with anakinra to prevent adverse cardiac remodeling after acute myocardial infarction (Virginia Commonwealth University Anakinra Remodeling Trial (VCU-ART) Pilot study). Am J Cardiol, 105 (10), 1371-1377 e1 (2010)
DOI: 10.1016/j.amjcard.2009.12.059

69. A. Abbate, B. W. Van Tassell, G. Biondi-Zoccai, M. C. Kontos, J. D. Grizzard, D. W. Spillman, C. Oddi, C. S. Roberts, R. D. Melchior, G. H. Mueller, N. A. Abouzaki, L. R. Rengel, A. Varma, M. L. Gambill, R. A. Falcao, N. F. Voelkel, C. A. Dinarello and G. W. Vetrovec: Effects of interleukin-1 blockade with anakinra on adverse cardiac remodeling and heart failure after acute myocardial infarction (from the Virginia Commonwealth University-Anakinra Remodeling Trial (2) (VCU-ART2) pilot study). Am J Cardiol, 111 (10), 1394-400 (2013)
DOI: 10.1016/j.amjcard.2013.01.287

70. A. Abbate, M. C. Kontos, N. A. Abouzaki, R. D. Melchior, C. Thomas, B. W. Van Tassell, C. Oddi, S. Carbone, C. R. Trankle, C. S. Roberts, G. H. Mueller, M. L. Gambill, S. Christopher, R. Markley, G. W. Vetrovec, C. A. Dinarello and G. Biondi-Zoccai: Comparative safety of interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot studies). Am J Cardiol, 115 (3), 288-92 (2015)
DOI: 10.1016/j.amjcard.2014.11.003

71. A. H. Gerards, S. de Lathouder, E. R. de Groot, B. A. Dijkmans and L. A. Aarden: Inhibition of cytokine production by methotrexate. Studies in healthy volunteers and patients with rheumatoid arthritis. Rheumatology (Oxford), 42 (10), 1189-96 (2003)
DOI: 10.1093/rheumatology/keg323

72. S. Herman, N. Zurgil, P. Langevitz, M. Ehrenfeld and M. Deutsch: Methotrexate selectively modulates TH1/TH2 balance in active rheumatoid arthritis patients. Clin Exp Rheumatol, 26 (2), 317-23 (2008)

73. A. B. Reiss, S. E. Carsons, K. Anwar, S. Rao, S. D. Edelman, H. Zhang, P. Fernandez, B. N. Cronstein and E. S. Chan: Atheroprotective effects of methotrexate on reverse cholesterol transport proteins and foam cell transformation in human THP-1 monocyte/macrophages. Arthritis Rheum, 58 (12), 3675-83 (2008)
DOI: 10.1002/art.24040

74. J. A. McPherson, K. G. Barringhaus, G. G. Bishop, J. M. Sanders, J. M. Rieger, S. E. Hesselbacher, L. W. Gimple, E. R. Powers, T. Macdonald, G. Sullivan, J. Linden and I. J. Sarembock: Adenosine A (2A) receptor stimulation reduces inflammation and neointimal growth in a murine carotid ligation model. Arterioscler Thromb Vasc Biol, 21 (5), 791-6 (2001)
DOI: 10.1161/01.ATV.21.5.791

75. A. Bulgarelli, A. A. Martins Dias, B. Caramelli and R. C. Maranhao: Treatment with methotrexate inhibits atherogenesis in cholesterol-fed rabbits. J Cardiovasc Pharmacol, 59 (4), 308-14 (2012)
DOI: 10.1097/FJC.0b013e318241c385

76. H. K. Choi, M. A. Hernan, J. D. Seeger, J. M. Robins and F. Wolfe: Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. Lancet, 359 (9313), 1173-7 (2002)
DOI: 10.1016/S0140-6736(02)08213-2

77. P. M. Ridker: Testing the inflammatory hypothesis of atherothrombosis: scientific rationale for the cardiovascular inflammation reduction trial (CIRT). J Thromb Haemost, 7 Suppl 1, 332-9 (2009)
DOI: 10.1111/j.1538-7836.2009.03404.x

78. R. Micha, F. Imamura, M. Wyler von Ballmoos, D. H. Solomon, M. A. Hernan, P. M. Ridker and D. Mozaffarian: Systematic review and meta-analysis of methotrexate use and risk of cardiovascular disease. Am J Cardiol, 108 (9), 1362-70 (2011)
DOI: 10.1016/j.amjcard.2011.06.054

79. https://clinicaltrials.gov/ct2/show/NC-T01594333

80. http://www.cardiobrief.org/2018/05/2-1/nih-halts-large-cardiovascular-inflammation-reduction-cirt-trial/

81. P. M. E. Ridker, B.M.; Pradhan, A.; MacFadyen, J.G.; Solomon, D.H.; Zaharris, E.; Mam, V.; Hasan, A.; Rosenberg, Y.; Iturriaga, E.; Gupta, M.; Tsigoulis, M.; Verma, S.; Clearfield, M.; Libby, P.; Goldhaber, S.Z.; Seagle, R.; Ofori, C.; Saklayen, M.; Butman, S.; Singh, N.; Le May, M.; Bertrand, O.; Johnston, J.; Paynter, N.P.; Glynn, R.J.; for the CIRT Investigators: Low-Dose Methotrexate for the Prevention of Atherosclerotic Events. New Engl J Med (2018)
DOI: 10.1056/NEJMoa1809798

82. S. Robertson, G. J. Martinez, C. A. Payet, J. Y. Barraclough, D. S. Celermajer, C. Bursill and S. PaTel: Colchicine therapy in acute coronary syndrome patients acts on caspase-1 to suppress NLRP3 inflammasome monocyte activation. Clin Sci (Lond), 130 (14), 1237-46 (2016)
DOI: 10.1042/CS20160090

83. G. J. Martinez, S. Robertson, J. Barraclough, Q. Xia, Z. Mallat, C. Bursill, D. S. Celermajer and S. PaTel: Colchicine Acutely Suppresses Local Cardiac Production of Inflammatory Cytokines in Patients With an Acute Coronary Syndrome. J Am Heart Assoc, 4 (8), e002128 (2015)
DOI: 10.1161/JAHA.115.002128

84. G. Nuki: Colchicine: its mechanism of action and efficacy in crystal-induced inflammation. Curr Rheumatol Rep, 10 (3), 218-27 (2008)
DOI: 10.1007/s11926-008-0036-3

85. J. H. O'Keefe, Jr., B. D. McCallister, T. M. Bateman, D. L. Kuhnlein, R. W. Ligon and G. O. Hartzler: Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty. J Am Coll Cardiol, 19 (7), 1597-600 (1992)
DOI: 10.1016/0735-1097(92)90624-V

86. S. Deftereos, G. Giannopoulos, K. Raisakis, C. Kossyvakis, A. Kaoukis, V. Panagopoulou, M. Driva, G. Hahalis, V. Pyrgakis, D. Alexopoulos, A. S. Manolis, C. Stefanadis and M. W. Cleman: Colchicine treatment for the prevention of bare-metal stent restenosis in diabetic patients. J Am Coll Cardiol, 61 (16), 1679-85 (2013)
DOI: 10.1016/j.jacc.2013.01.055

87. G. Giannopoulos, C. Angelidis, V. K. Kouritas, P. Dedeilias, G. Filippatos, M. W. Cleman, V. Panagopoulou, G. Siasos, D. Tousoulis, J. Lekakis and S. Deftereos: Usefulness of colchicine to reduce perioperative myocardial damage in patients who underwent on-pump coronary artery bypass grafting. Am J Cardiol, 115 (10), 1376-81 (2015)
DOI: 10.1016/j.amjcard.2015.02.036

88. P. Langevitz, A. Livneh, L. Neumann, D. Buskila, J. Shemer, D. Amolsky and M. Pras: Prevalence of ischemic heart disease in patients with familial Mediterranean fever. Isr Med Assoc J, 3 (1), 9-12 (2001)

89. D. B. Crittenden, R. A. Lehmann, L. Schneck, R. T. Keenan, B. Shah, J. D. Greenberg, B. N. Cronstein, S. P. Sedlis and M. H. Pillinger: Colchicine use is associated with decreased prevalence of myocardial infarction in patients with gout. J Rheumatol, 39 (7), 1458-64 (2012)
DOI: 10.3899/jrheum.111533

90. S. M. Nidorf, J. W. Eikelboom, C. A. Budgeon and P. L. Thompson: Low-dose colchicine for secondary prevention of cardiovascular disease. J Am Coll Cardiol, 61 (4), 404-10 (2013)
DOI: 10.1016/j.jacc.2012.10.027

91. S. Verma, J. W. Eikelboom, S. M. Nidorf, M. Al-Omran, N. Gupta, H. Teoh and J. O. Friedrich: Colchicine in cardiac disease: a systematic review and meta-analysis of randomized controlled trials. BMC Cardiovasc Disord, 15, 96 (2015)
DOI: 10.1186/s12872-015-0068-3

92. D. H. Solomon, C. C. Liu, I. H. Kuo, A. Zak and S. C. Kim: Effects of colchicine on risk of cardiovascular events and mortality among patients with gout: a cohort study using electronic medical records linked with Medicare claims. Ann Rheum Dis, 75 (9), 1674-9 (2016)
DOI: 10.1136/annrheumdis-2015-207984

93. K. Vaidya, C. Arnott, G. J. Martinez, B. Ng, S. McCormack, D. R. Sullivan, D. S. Celermajer and S. PaTel: Colchicine Therapy and Plaque Stabilization in Patients With Acute Coronary Syndrome: A CT Coronary Angiography Study. JACC Cardiovasc Imaging, 11 (2 Pt 2), 305-316 (2018)
DOI: 10.1016/j.jcmg.2017.08.013

94. https://www.anzctr.org.au/Trial/Regis-tration/TrialReview.aspx?ACTRN=12614000093684

95. https://clinicaltrials.gov/ct2/show/NC-T02551094

96. Y. Sawa, H. Ichikawa, K. Kagisaki, T. Ohata and H. Matsuda: Interleukin-6 derived from hypoxic myocytes promotes neutrophil-mediated reperfusion injury in myocardium. J Thorac Cardiovasc Surg, 116 (3), 511-7 (1998)
DOI: 10.1016/S0022-5223(98)70018-2

97. P. Zamani, G. G. Schwartz, A. G. Olsson, N. Rifai, W. Bao, P. Libby, P. Ganz, S. Kinlay and I. Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study: Inflammatory biomarkers, death, and recurrent nonfatal coronary events after an acute coronary syndrome in the MIRACL study. J Am Heart Assoc, 2 (1), e003103 (2013)
DOI: 10.1161/JAHA.112.003103

98. E. Frisdal, P. Lesnik, M. Olivier, P. Robillard, M. J. Chapman, T. Huby, M. Guerin and W. Le Goff: Interleukin-6 protects human macrophages from cellular cholesterol accumulation and attenuates the proinflammatory response. J Biol Chem, 286 (35), 30926-36 (2011)
DOI: 10.1074/jbc.M111.264325

99. R. Starkie, S. R. Ostrowski, S. Jauffred, M. Febbraio and B. K. Pedersen: Exercise and IL-6 infusion inhibit endotoxin-induced TNF-alpha production in humans. FASEB J, 17 (8), 884-6 (2003)
DOI: 10.1096/fj.02-0670fje

100. H. Tilg, C. A. Dinarello and J. W. Mier: IL-6 and APPs: anti-inflammatory and immunosuppressive mediators. Immunol Today, 18 (9), 428-32 (1997)
DOI: 10.1016/S0167-5699(97)01103-1

101. H. Tilg, E. Trehu, M. B. Atkins, C. A. Dinarello and J. W. Mier: Interleukin-6 (IL-6) as an anti-inflammatory cytokine: induction of circulating IL-1 receptor antagonist and soluble tumor necrosis factor receptor p55. Blood, 83 (1), 113-8 (1994)

102. R. Schindler, J. Mancilla, S. Endres, R. Ghorbani, S. C. Clark and C. A. Dinarello: Correlations and interactions in the production of interleukin-6 (IL-6), IL-1, and tumor necrosis factor (TNF) in human blood mononuclear cells: IL-6 suppresses IL-1 and TNF. Blood, 75 (1), 40-7 (1990)

103. C. Gabay, I. B. McInnes, A. Kavanaugh, K. Tuckwell, M. Klearman, J. Pulley and N. Sattar: Comparison of lipid and lipid-associated cardiovascular risk marker changes after treatment with tocilizumab or adalimumab in patients with rheumatoid arthritis. Ann Rheum Dis, 75 (10), 1806-12 (2016)
DOI: 10.1136/annrheumdis-2015-207872

104. J. S. Lee, M. J. Chapman, P. Piraino, J. Lamerz, T. Schindler, P. Cutler and G. Dernick: Remodeling of plasma lipoproteins in patients with rheumatoid arthritis: Interleukin-6 receptor-alpha inhibition with tocilizumab. Proteomics Clin Appl, 10 (2), 183-94 (2016)
DOI: 10.1002/prca.201500036

105. N. Muller, D. M. Schulte, K. Turk, S. Freitag-Wolf, J. Hampe, R. Zeuner, J. O. Schroder, I. Gouni-Berthold, H. K. Berthold, W. Krone, S. Rose-John, S. Schreiber and M. Laudes: IL-6 blockade by monoclonal antibodies inhibits apolipoprotein (a) expression and lipoprotein (a) synthesis in humans. J Lipid Res, 56 (5), 1034-42 (2015)
DOI: 10.1194/jlr.P052209

106. O. Schultz, F. Oberhauser, J. Saech, A. Rubbert-Roth, M. Hahn, W. Krone and M. Laudes: Effects of inhibition of interleukin-6 signalling on insulin sensitivity and lipoprotein (a) levels in human subjects with rheumatoid diseases. PLoS One, 5 (12), e14328 (2010)
DOI: 10.1371/journal.pone.0014328

107. https://clinicaltrials.gov/ct2/show/NC-T02659150

108. X. Wang, G. Z. Feuerstein, J. L. Gu, P. G. Lysko and T. L. Yue: Interleukin-1 beta induces expression of adhesion molecules in human vascular smooth muscle cells and enhances adhesion of leukocytes to smooth muscle cells. Atherosclerosis, 115 (1), 89-98 (1995)
DOI: 10.1016/0021-9150(94)05503-B

109. A. Mantovani, M. A. Cassatella, C. Costantini and S. Jaillon: Neutrophils in the activation and regulation of innate and adaptive immunity. Nat Rev Immunol, 11 (8), 519-31 (2011)
DOI: 10.1038/nri3024

110. J. M. Lambert, E. F. Lopez and M. L. Lindsey: Macrophage roles following myocardial infarction. Int J Cardiol, 130 (2), 1477-58 (2008)
DOI: 10.1016/j.ijcard.2008.04.059

111. A. Tedgui and Z. Mallat: Cytokines in atherosclerosis: pathogenic and regulatory pathways. Physiol Rev, 86 (2), 515-81 (2006)
DOI: 10.1152/physrev.00024.2005

112. J. Galea, J. Armstrong, P. Gadsdon, H. Holden, S. E. Francis and C. M. Holt: Interleukin-1 beta in coronary arteries of patients with ischemic heart disease. Arterioscler Thromb Vasc Biol, 16 (8), 1000-6 (1996)
DOI: 10.1161/01.ATV.16.8.1000

113. P. M. Ridker, B. M. Everett, T. Thuren, J. G. MacFadyen, W. H. Chang, C. Ballantyne, F. Fonseca, J. Nicolau, W. Koenig, S. D. Anker, J. J. P. Kastelein, J. H. Cornel, P. Pais, D. Pella, J. Genest, R. Cifkova, A. Lorenzatti, T. Forster, Z. Kobalava, L. Vida-Simiti, M. Flather, H. Shimokawa, H. Ogawa, M. Dellborg, P. R. F. Rossi, R. P. T. Troquay, P. Libby, R. J. Glynn, C. T. Group: Antiinflammatory Therapy with Canakinumab for Atherosclerotic Disease. New Engl J Med, 377 (12), 1119-1131 (2017)
DOI: 10.1056/NEJMoa1707914

114. P. M. Ridker, J. G. MacFadyen, B. M. Everett, P. Libby, T. Thuren, R. J. Glynn and C. T. Group: Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial. Lancet, 391 (10118), 319-328 (2018)
DOI: 10.1016/S0140-6736(17)32814-3

115. P. M. Ridker, P. Libby, J. G. MacFadyen, T. Thuren, C. Ballantyne, F. Fonseca, W. Koenig, H. Shimokawa, B. M. Everett, R. J. Glynn. Modulation of the interleukin-6 signalling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-Inflammatory Thrombosis Outcomes Study (CANTOS). Eur Heart J, 39 (38), 3499-3507 (2018)
DOI: 10.1093/eurheartj/ehy310

116. https://www.medscape.com/viewarticle-/903618

117. https://clinicaltrials.gov/ct2/show/NCT0-1327846

118. https://clinicaltrials.gov/ct2/show/NCT0-3072199

119. T. van der Heijden, E. Kritikou, W. Venema, J. van Duijn, P. J. van Santbrink, B. Slutter, A. C. Foks, I. Bot and J. Kuiper: NLRP3 Inflammasome Inhibition by MCC950 Reduces Atherosclerotic Lesion Development in Apolipoprotein E-Deficient Mice-Brief Report. Arterioscler Thromb Vasc Biol, 37 (8), 1457-1461 (2017)
DOI: 10.1161/ATVBAHA.117.309575

120. A. Abderrazak, D. Couchie, D. F. Mahmood, R. Elhage, C. Vindis, M. Laffargue, V. Mateo, B. Buchele, M. R. Ayala, M. El Gaafary, T. Syrovets, M. N. Slimane, B. Friguet, T. Fulop, T. Simmet, K. El Hadri and M. Rouis: Anti-inflammatory and antiatherogenic effects of the NLRP3 inflammasome inhibitor arglabin in ApoE2.Ki mice fed a high-fat diet. Circulation, 131 (12), 1061-70 (2015)
DOI: 10.1161/CIRCULATIONAHA.114.013730

121. L. Gu, Y. Okada, S. K. Clinton, C. Gerard, G. K. Sukhova, P. Libby and B. J. Rollins: Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell, 2 (2), 275-81 (1998)
DOI: 10.1016/S1097-2765(00)80139-2

122. J. Gosling, S. Slaymaker, L. Gu, S. Tseng, C. H. Zlot, S. G. Young, B. J. Rollins and I. F. Charo: MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J Clin Invest, 103 (6), 773-8 (1999)
DOI: 10.1172/JCI5624

123. L. Boring, J. Gosling, M. Cleary and I. F. Charo: Decreased lesion formation in CCR2-/- mice reveals a role for chemokines in the initiation of atherosclerosis. Nature, 394 (6696), 894-7 (1998)
DOI: 10.1038/29788

124. S. Piconi, D. Pocaterra, V. Rainone, M. Cossu, M. Masetti, G. Rizzardini, M. Clerici and D. Trabattoni: Maraviroc Reduces Arterial Stiffness in PI-Treated HIV-infected Patients. Sci Rep, 6, 28853 (2016)
DOI: 10.1038/srep28853

125. R. R. Koenen, P. von Hundelshausen, I. V. Nesmelova, A. Zernecke, E. A. Liehn, A. Sarabi, B. K. Kramp, A. M. Piccinini, S. R. Paludan, M. A. Kowalska, A. J. Kungl, T. M. Hackeng, K. H. Mayo and C. Weber: Disrupting functional interactions between platelet chemokines inhibits atherosclerosis in hyperlipidemic mice. Nat Med, 15 (1), 97-103 (2009)
DOI: 10.1038/nm.1898

126. E. Lutgens, D. Lievens, L. Beckers, E. Wijnands, O. Soehnlein, A. Zernecke, T. Seijkens, D. Engel, J. Cleutjens, A. M. Keller, S. H. Naik, L. Boon, H. A. Oufella, Z. Mallat, C. L. Ahonen, R. J. Noelle, M. P. de Winther, M. J. Daemen, E. A. Biessen and C. Weber: Deficient CD40-TRAF6 signaling in leukocytes prevents atherosclerosis by skewing the immune response toward an antiinflammatory profile. J Exp Med, 207 (2), 391-404 (2010)
DOI: 10.1084/jem.20091293

127. M. M. Donners, L. Beckers, D. Lievens, I. Munnix, J. Heemskerk, B. J. Janssen, E. Wijnands, J. Cleutjens, A. Zernecke, C. Weber, C. L. Ahonen, U. Benbow, A. C. Newby, R. J. Noelle, M. J. Daemen and E. Lutgens: The CD40-TRAF6 axis is the key regulator of the CD40/CD40L system in neointima formation and arterial remodeling. Blood, 111 (9), 4596-604 (2008)
DOI: 10.1182/blood-2007-05-088906

128. T. T. P. Seijkens, C. M. van Tiel, P. J. H. Kusters, D. Atzler, O. Soehnlein, B. Zarzycka, S. Aarts, M. Lameijer, M. J. Gijbels, L. Beckers, M. den Toom, B. Slutter, J. Kuiper, J. Duchene, M. Aslani, R. T. A. Megens, C. van 't Veer, G. Kooij, R. Schrijver, M. A. Hoeksema, L. Boon, F. Fay, J. Tang, S. Baxter, A. Jongejan, P. D. Moerland, G. Vriend, B. Bleijlevens, E. A. Fisher, R. Duivenvoorden, N. Gerdes, M. P. J. de Winther, G. A. Nicolaes, W. J. M. Mulder, C. Weber and E. Lutgens: Targeting CD40-Induced TRAF6 Signaling in Macrophages Reduces Atherosclerosis. J Am Coll Cardiol, 71 (5), 527-542 (2018)
DOI: 10.1016/j.jacc.2017.11.055

129. F. Mach, U. Schonbeck, G. K. Sukhova, E. Atkinson and P. Libby: Reduction of atherosclerosis in mice by inhibition of CD40 signalling. Nature, 394 (6689), 200-3 (1998)
DOI: 10.1038/28204

130. U. Schonbeck, G. K. Sukhova, K. Shimizu, F. Mach and P. Libby: Inhibition of CD40 signaling limits evolution of established atherosclerosis in mice. Proc Natl Acad Sci U S A, 97 (13), 7458-63 (2000)
DOI: 10.1073/pnas.97.13.7458

131. I. Rashid, G. J. Maghzal, Y. C. Chen, D. Cheng, J. Talib, D. Newington, M. Ren, S. K. Vajandar, A. Searle, A. Maluenda, E. L. Lindstedt, A. Jabbour, A. J. Kettle, A. Bongers, C. Power, E. Michaelsson, K. Peter and R. Stocker: Myeloperoxidase is a potential molecular imaging and therapeutic target for the identification and stabilization of high-risk atherosclerotic plaque. Eur Heart J, 39 (35), 3301-3310 (2018)
DOI: 10.1093/eurheartj/ehy419

132. Y. Tashiro, K. Sato, T. Watanabe, K. Nohtomi, M. Terasaki, M. Nagashima and T. Hirano: A glucagon-like peptide-1 analog liraglutide suppresses macrophage foam cell formation and atherosclerosis. Peptides, 54, 19-26 (2014)
DOI: 10.1016/j.peptides.2013.12.015

133. J. Koreth, K. Matsuoka, H. T. Kim, S. M. McDonough, B. Bindra, E. P. Alyea, 3rd, P. Armand, C. Cutler, V. T. Ho, N. S. Treister, D. C. Bienfang, S. Prasad, D. Tzachanis, R. M. Joyce, D. E. Avigan, J. H. Antin, J. Ritz and R. J. Soiffer: Interleukin-2 and regulatory T cells in graft-versus-host disease. N Engl J Med, 365 (22), 2055-66 (2011)
DOI: 10.1056/NEJMoa1108188

134. K. Matsuoka, J. Koreth, H. T. Kim, G. Bascug, S. McDonough, Y. Kawano, K. Murase, C. Cutler, V. T. Ho, E. P. Alyea, P. Armand, B. R. Blazar, J. H. Antin, R. J. Soiffer and J. Ritz: Low-dose interleukin-2 therapy restores regulatory T cell homeostasis in patients with chronic graft-versus-host disease. Sci Transl Med, 5 (179), 179ra43 (2013)
DOI: 10.1126/scitranslmed.3005265

135. D. Saadoun, M. Rosenzwajg, F. Joly, A. Six, F. Carrat, V. Thibault, D. Sene, P. Cacoub and D. Klatzmann: Regulatory T-cell responses to low-dose interleukin-2 in HCV-induced vasculitis. N Engl J Med, 365 (22), 2067-77 (2011)
DOI: 10.1056/NEJMoa1105143

136. https://clinicaltrials.gov/ct2/show/NCT0-3113773

137. H. Tamai, O. Katoh, S. Suzuki, K. Fujii, T. Aizawa, S. Takase, H. Kurogane, H. Nishikawa, T. Sone, K. Sakai and T. Suzuki: Impact of tranilast on restenosis after coronary angioplasty: tranilast restenosis following angioplasty trial (TREAT). Am Heart J, 138 (5 Pt 1), 968-75 (1999)
DOI: 10.1016/S0002-8703(99)70025-6

138. H. Tamai, K. Katoh, T. Yamaguchi, H. Hayakawa, K. Kanmatsuse, K. Haze, T. Aizawa, S. Nakanishi, S. Suzuki, T. Suzuki, S. Takase, H. Nishikawa and O. Katoh: The impact of tranilast on restenosis after coronary angioplasty: the Second Tranilast Restenosis Following Angioplasty Trial (TREAT-2). Am Heart J, 143 (3), 506-13 (2002)
DOI: 10.1067/mhj.2002.120770

139. M. L. O'Donoghue, E. Braunwald, H. D. White, M. A. Lukas, E. Tarka, P. G. Steg, J. S. Hochman, C. Bode, A. P. Maggioni, K. Im, J. B. Shannon, R. Y. Davies, S. A. Murphy, S. E. Crugnale, S. D. Wiviott, M. P. Bonaca, D. F. Watson, W. D. Weaver, P. W. Serruys, C. P. Cannon, S.-T. Investigators and D. L. Steen: Effect of darapladib on major coronary events after an acute coronary syndrome: the SOLID-TIMI 52 randomized clinical trial. JAMA, 312 (10), 1006-15 (2014)
DOI: 10.1001/jama.2014.11061

140. S. Investigators, H. D. White, C. Held, R. Stewart, E. Tarka, R. Brown, R. Y. Davies, A. Budaj, R. A. Harrington, P. G. Steg, D. Ardissino, P. W. Armstrong, A. Avezum, P. E. Aylward, A. Bryce, H. Chen, M. F. Chen, R. Corbalan, A. J. Dalby, N. Danchin, R. J. De Winter, S. Denchev, R. Diaz, M. Elisaf, M. D. Flather, A. R. Goudev, C. B. Granger, L. Grinfeld, J. S. Hochman, S. Husted, H. S. Kim, W. Koenig, A. Linhart, E. Lonn, J. Lopez-Sendon, A. J. Manolis, E. R. Mohler, 3rd, J. C. Nicolau, P. Pais, A. Parkhomenko, T. R. Pedersen, D. Pella, M. A. Ramos-Corrales, M. Ruda, M. Sereg, S. Siddique, P. Sinnaeve, P. Smith, P. Sritara, H. P. Swart, R. G. Sy, T. Teramoto, H. F. Tse, D. Watson, W. D. Weaver, R. Weiss, M. Viigimaa, D. Vinereanu, J. Zhu, C. P. Cannon and L. Wallentin: Darapladib for preventing ischemic events in stable coronary heart disease. N Engl J Med, 370 (18), 1702-11 (2014)
DOI: 10.1056/NEJMoa1315878

141. L. K. Newby, M. S. Marber, C. Melloni, L. Sarov-Blat, L. H. Aberle, P. E. Aylward, G. Cai, R. J. de Winter, C. W. Hamm, J. F. Heitner, R. Kim, A. Lerman, M. R. Patel, J. F. Tanguay, J. J. Lepore, H. R. Al-Khalidi, D. L. Sprecher, C. B. Granger and S. Investigators: Losmapimod, a novel p38 mitogen-activated protein kinase inhibitor, in non-ST-segment elevation myocardial infarction: a randomised phase 2 trial. Lancet, 384 (9949), 1187-95 (2014)
DOI: 10.1016/S0140-6736(14)60417-7

142. M. L. O'Donoghue, R. Glaser, M. A. Cavender, P. E. Aylward, M. P. Bonaca, A. Budaj, R. Y. Davies, M. Dellborg, K. A. Fox, J. A. Gutierrez, C. Hamm, R. G. Kiss, F. Kovar, J. F. Kuder, K. A. Im, J. J. Lepore, J. L. Lopez-Sendon, T. O. Ophuis, A. Parkhomenko, J. B. Shannon, J. Spinar, J. F. Tanguay, M. Ruda, P. G. Steg, P. Theroux, S. D. Wiviott, I. Laws, M. S. Sabatine, D. A. Morrow and L.-T. Investigators: Effect of Losmapimod on Cardiovascular Outcomes in Patients Hospitalized With Acute Myocardial Infarction: A Randomized Clinical Trial. JAMA, 315 (15), 1591-9 (2016)
DOI: 10.1001/jama.2016.3609

143. O. Kleveland, G. Kunszt, M. Bratlie, T. Ueland, K. Broch, E. Holte, A. E. Michelsen, B. Bendz, B. H. Amundsen, T. Espevik, S. Aakhus, J. K. Damas, P. Aukrust, R. Wiseth and L. Gullestad: Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial. Eur Heart J, 37 (30), 2406-13 (2016)
DOI: 10.1093/eurheartj/ehw171

144. S. C. Kim, D. H. Solomon, J. R. Rogers, S. Gale, M. Klearman, K. Sarsour and S. Schneeweiss: Cardiovascular Safety of Tocilizumab Versus Tumor Necrosis Factor Inhibitors in Patients With Rheumatoid Arthritis: A Multi-Database Cohort Study. Arthritis Rheumatol, 69 (6), 1154-1164 (2017)
DOI: 10.1002/art.40084

145. M. B. Carroll, C. Haller and C. Smith: Short-term application of tocilizumab during myocardial infarction (STAT-MI). Rheumatol Int, 38 (1), 59-66 (2018)
DOI: 10.1007/s00296-017-3842-y

Key Words: Inflammation, Atherosclerosis, Human, Clinical Trials, Review

Send correspondence to: Duygu Kocyigit, Cardiology Clinics, Afyonkarahisar Dinar State Hospital, 03400, Afyonkarahisar, Turkey, Tel: 0090-272-3536099, Fax: 0090-272-3534017, E-mail: kocyigitduygu@yahoo.com